Personalis: Medicare Reimbursement for Breast Cancer Monitoring Provides Boost – Analysts See 20% Chance!
Reading Time: 1 minute
Personalis (PSNL) has specialized as a diagnostic company in precision oncology. One of its core products is NeXT Personal, which is used for the detection of minimal residual disease (MRD) and recurrent cancer (recurrence), capable of identifying minute traces of tumor DNA (ctDNA) in blood samples before they become visible through imaging. Precedence Research estimates that the global MRD testing market will grow from $1.7 billion to over $4.7 billion by 2034. On November 10, Medicare reimbursement for monitoring breast cancer patients in...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
